{"id":341029,"date":"2026-03-11T18:58:07","date_gmt":"2026-03-11T18:58:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/341029\/"},"modified":"2026-03-11T18:58:07","modified_gmt":"2026-03-11T18:58:07","slug":"disrupting-protein-production-in-tumors-triggers-potent-immune-responses","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/341029\/","title":{"rendered":"Disrupting protein production in tumors triggers potent immune responses"},"content":{"rendered":"<p>A new study led by Pierre Close&#8217;s team (GIGA, Laboratory of Cancer Signaling, and WELRI Investigator) reveals how subtly disrupting the way tumors produce their proteins can trigger a potent antitumor immune response.<\/p>\n<p>Researchers from the University of Li\u00e8ge and international collaborators have discovered an unexpected way to to stimulate the immune system against cancer: by subtly disrupting how tumor cells manufacture their proteins.<\/p>\n<p>The study, recently accepted for publication in Nature Communications, reveals that cancer cells rely on a highly precise protein-production system to remain to evade immune attack. When this system is perturbed, tumors can suddenly become vulnerable to immune recognition and elimination by the body&#8217;s own defenses.<\/p>\n<p>When protein quality control becomes cancer&#8217;s shield<\/p>\n<p>All cells constantly produce proteins based on genetic instructions. To do this accurately, they rely on molecular &#8220;adaptors&#8221; called transfer RNAs (tRNAs), which ensure proteins are built correctly. Cancer cells exploit this system to maintain stability and avoid triggering immune responses.<\/p>\n<p>The research team discovered that a specific tRNA modification, controlled by an enzyme called KEOPS, plays a crucial role in helping <a href=\"https:\/\/www.news-medical.net\/health\/What-are-Melanomas.aspx\" class=\"linked-term\" rel=\"nofollow noopener\" target=\"_blank\">melanoma<\/a> tumors evade immune detection. When this modification is disrupted, cancer cells begin producing misfolded proteins that accumulate inside the cell.<\/p>\n<p>&#8220;By disrupting this quality\u2011control mechanism, we force the tumor to reveal what it normally works hard to hide,&#8221; explains Pierre Close, Director of the Laboratory of Cancer Signaling. &#8220;This buildup of faulty proteins acts as a warning signal: it triggers an immune response similar to the one activated during viral infections. It&#8217;s an entirely new way of activating antitumor immunity.&#8221;<\/p>\n<p>Rather than being harmless, this buildup acts as a distress signal: it activates an innate immune sensor normally used to detect viral infections. This, in turn, attracts and activates immune <a href=\"https:\/\/www.news-medical.net\/health\/What-are-T-Cells.aspx\" class=\"linked-term\" rel=\"nofollow noopener\" target=\"_blank\">T cells<\/a>, which infiltrate the tumor and drive its rejection.<\/p>\n<p>In preclinical models, blocking this pathway transformed &#8220;cold&#8221; tumors, typically unresponsive to immune attack, into &#8220;hot&#8221; tumors that became infiltrated by immune cells and showed markedly reduced growth.<\/p>\n<p>A new strategy to make resistant tumors treatable<\/p>\n<p>Immunotherapies have revolutionized cancer treatment, but many tumors remain resistant because they evade effective immune attack. This study highlights a fundamentally new approach: instead of directly stimulating immune cells, researchers can render tumor cells more susceptible to antitumor immunity by altering how they produce proteins..<\/p>\n<p>&#8220;Our work shows that the stability of protein production can become a true Achilles&#8217; heel for tumors,&#8221; says Cl\u00e9a Dziagwa, T\u00e9l\u00e9vie PhD candidate and first author of the publication. &#8220;Understanding how tRNAs influence immune evasion opens the possibility of intervening where conventional immunotherapies fail.&#8221;<\/p>\n<p>By linking RNA biology, protein quality control and anti-tumor immunity, the work opens new avenues for therapeutic development. Targeting tRNA modifications could represent a strategy to enhance current immunotherapies or to treat cancers that currently do not respond.<\/p>\n<p>From fundamental discovery to translational ambition<\/p>\n<p>This work was carried out at the GIGA Institute of the University of Li\u00e8ge, in collaboration with international partners in the UK and Germany, and supported by FNRS and WELRI\/WELBIO. It reflects the growing strength of Belgian research in RNA biology and cancer immunology.<\/p>\n<p>For clinician-scientists involved in the project, the findings also shape future ambitions: translating discoveries on RNA and protein synthesis into new therapeutic strategies for difficult-to-treat cancers. By understanding how tumors control their internal protein machinery to escape immune detection, researchers hope to design interventions that re-engage the immune system and improve patient outcomes.<\/p>\n<p>Ultimately, this study underscores a central idea: sometimes, making cancer vulnerable is not about attacking it directly, but about revealing it to the immune system.<\/p>\n<p>Source:<\/p>\n<p>Journal reference:<\/p>\n<p>Dziagwa, C., et al. (2026). Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.\u00a0Nature Communications. DOI: 10.1038\/s41467-026-69964-2.\u00a0<a href=\"https:\/\/www.nature.com\/articles\/s41467-026-69964-2\" rel=\"noopener nofollow\" target=\"_blank\">https:\/\/www.nature.com\/articles\/s41467-026-69964-2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"A new study led by Pierre Close&#8217;s team (GIGA, Laboratory of Cancer Signaling, and WELRI Investigator) reveals how&hellip;\n","protected":false},"author":2,"featured_media":13626,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[258,2164,31399,61,22005,3176,3177,60,9567,21704,2682,55761,89,1244,80],"class_list":["post-341029","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-cancer","tag-electron","tag-electron-microscopy","tag-ie","tag-immune-response","tag-immune-system","tag-immunity","tag-ireland","tag-laboratory","tag-microscopy","tag-protein","tag-quality-control","tag-research","tag-rna","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/341029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=341029"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/341029\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/13626"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=341029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=341029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=341029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}